Abstract
Tissue reperfusion is a serious therapeutic strategy of ischemic stroke in addition to recanalization. In this work, we aimed to establish new urokinase-based therapeutics in order to dissolve large vessel thrombus together with microthrombi for stroke implications. Formulations consisted of free urokinase (UK), polyethylene glycol–crosslinked urokinase nanogel (PEG-UK), and a 1:1 mixture of UK and PEG-UK (PEG-UK+UK) were tested both in vitro and in vivo. In vitro experiments confirmed the pH-dependent release of PEG-UK in the PEG-UK+UK formulation. It was activated at pH 6.50, an environmental pH in the infarct brain tissue, owing to the dynamic crosslink property of PEG-UK. In vivo tests on a thromboembolic stroke rat model showed that the formulations containing UK, i.e., free UK and PEG-UK+UK, demonstrated better neurological scores and smaller infarction volumes within the time window, in which the PEG-UK+UK formulation relatively performed better. On the other hand, the formulations containing PEG-UK, i.e., PEG-UK and PEG-UK+UK, gained sufficient thrombolytic efficiency beyond the time window. Further investigation on the mechanism revealed that PEG-UK could reduce microthrombus in distal microcirculation, and its destructive effect was also less than that of free UK. The PEG-UK+UK formulation actually provided a “dual targeting” delivery of UK to both the large vessels and the microcirculation, which was beneficial to the treatment of cerebral ischemic stroke both within and beyond the therapeutic time window.
Similar content being viewed by others
Abbreviations
- CCA:
-
common carotid artery
- ECA:
-
external carotid artery
- Hb:
-
hemoglobin
- H&E:
-
hematoxylin-eosin
- HT:
-
hemorrhagic transformation
- ICA:
-
internal carotid artery
- MCAO:
-
middle cerebral artery occlusion
- MRA:
-
magnetic resonance angiography
- OD:
-
optical density
- OHC-PEG-CHO:
-
benzaldehyde-terminated PEG
- PEG:
-
polyethylene glycol
- PEG-UK:
-
PEG-urokinase nanogels
- SEM:
-
scanning electron microscopy
- TTC:
-
2,3,5-triphenyltetrazolium chloride
- UK:
-
urokinase
References
Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parmar PG, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379:2429–37.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30.
del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke. 1991;22:1276–83.
Little John R, Kerr Frederick WL, Sundt Thoralf M. Microcirculatory obstruction in focal cerebral ischemia: an electron microscopic investigation in monkeys. Stroke. 1976;7:25–30.
Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke. 2005;36:2400–3.
Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol. 2006;60:508–17.
De Silva DA, Fink JN, Christensen S, Ebinger M, Bladin C, Levi CR, et al. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). Stroke. 2009;40:2872–4.
Tomsick T, Broderick J, Carrozella J, Khatri P, Hill M, Palesch Y, et al. Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008;29:582–7.
Dalkara T, Arsava EM. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis? J Cereb Blood Flow Metab. 2012;32:2091–9.
Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke. 2013;44:2650–63.
Alexandrov AV, Hall CE, Labiche LA, Wojner AW, Grotta JC. Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke. 2004;35:449–52.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e110.
Nedergaard M, Kraig RP, Tanabe J, Pulsinelli WA. Dynamics of interstitial and intracellular pH in evolving brain infarct. Am J Phys. 1991;260:R581–8.
Sako K, Kobatake K, Yamamoto YL, Diksic M. Correlation of local cerebral blood flow, glucose utilization, and tissue pH following a middle cerebral artery occlusion in the rat. Stroke. 1985;16:828–34.
Tan H, Jin H, Mei H, Zhu L, Wei W, Wang Q, et al. PEG-urokinase nanogels with enhanced stability and controllable bioactivity. Soft Matter. 2012;8:2644–50.
Zhao L, Zhu L, Liu F, Liu C, Shan D, Wang Q, et al. pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel. Int J Pharm. 2011;410:83–91.
Cui W, Liu R, Jin H, Lv P, Sun Y, Men X, et al. pH gradient difference around ischemic brain tissue can serve as a trigger for delivering polyethylene glycol-conjugated urokinase nanogels. J Control Release. 2016;225:53–63.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–703.
de Los Rios la Rosa F, Khoury J, Kissela BM, Flaherty ML, Alwell K, Moomaw CJ, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: the effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke. 2012;43:1591–5.
An H, Ford AL, Eldeniz C, Chen Y, Vo KD, Zhu H, et al. Reperfusion beyond 6 hours reduces infarct probability in moderately ischemic brain tissue. Stroke. 2016;47:99–105.
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18.
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11–21.
Jin H, Tan H, Zhao L, Sun W, Zhu L, Sun Y, et al. Ultrasound-triggered thrombolysis using urokinase-loaded nanogels. Int J Pharm. 2012;434:384–90.
Colasuonno M, Palange AL, Aid R, Ferreira M, Mollica H, Palomba R, et al. Erythrocyte-inspired discoidal polymeric nanoconstructs carrying tissue plasminogen activator for the enhanced lysis of blood clots. ACS Nano. 2018;12:12224–37.
Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–6.
Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010;468:232–43.
Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci. 2004;5:347–60.
Heye N, Cervos-Navarro J. Microthromboemboli in acute infarcts: analysis of 40 autopsy cases. Stroke. 1996;27:431–4.
Zhang Z, Davies K, Prostak J, Fenstermacher J, Chopp M. Quantitation of microvascular plasma perfusion and neuronal microtubule-associated protein in ischemic mouse brain by laser-scanning confocal microscopy. J Cereb Blood Flow Metab. 1999;19:68–78.
Zhang ZG, Chopp M, Goussev A, Lu D, Morris D, Tsang W, et al. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci. 1999;19:10898–907.
Wang E, Wu Y, Cheung JS, Igarashi T, Wu L, Zhang X, et al. Mapping tissue pH in an experimental model of acute stroke - determination of graded regional tissue pH changes with non-invasive quantitative amide proton transfer MRI. NeuroImage. 2019;191:610–7.
Chen Y, Zhu W, Zhang W, Libal N, Murphy SJ, Offner H, et al. A novel mouse model of thromboembolic stroke. J Neurosci Methods. 2015;256:203–11.
Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54:459–76.
Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214–21.
Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke. 1999;30:1326–32.
Schwab S, Steiner T, Aschoff A, Schwarz S, Steiner HH, Jansen O, et al. Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke. 1998;29:1888–93.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28:2109–18.
Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957–60.
Desilles JP, Loyau S, Syvannarath V, Gonzalez-Valcarcel J, Cantier M, Louedec L, et al. Alteplase reduces downstream microvascular thrombosis and improves the benefit of large artery recanalization in stroke. Stroke. 2015;46:3241–8.
Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke. 2002;33:1077–84.
Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab. 2014;34:185–99.
Rosell A, Foerch C, Murata Y, Lo EH. Mechanisms and markers for hemorrhagic transformation after stroke. Acta Neurochir Suppl. 2008;105:173–8.
Acknowledgments
The authors thank Zhang Baogui from the Chinese Academy of Sciences-Institute of Automation Center for Advanced Imaging for the MR scan of rats.
Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81971115, No. 81400941, No. 51773119, No. 82071306).
Author information
Authors and Affiliations
Contributions
Ding Nan and Haiqiang Jin performed the experiments, analyzed and interpreted the data, and wrote the manuscript; Di Yang, Weiwei Yu, Jingjing Jia, Zemou Yu, Yongan Sun, Hongjun Hao, and Hui Tan aided in the preparation of the manuscript; Xiaozhong Qu supervised the study; Yining Huang supervised the study and provided financial support; and all authors revised the manuscript and approved its final version.
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All experiments were performed according to the Guideline for the Care and Use of Experimental Animals of Peking University First Hospital (J201890).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
First author: Ding Nan and Haiqiang Jin
Electronic Supplementary Material
ESM 1
(DOCX 3037 kb)
Rights and permissions
About this article
Cite this article
Nan, D., Jin, H., Yang, D. et al. Combination of Polyethylene Glycol-Conjugated Urokinase Nanogels and Urokinase for Acute Ischemic Stroke Therapeutic Implications. Transl. Stroke Res. 12, 844–857 (2021). https://doi.org/10.1007/s12975-020-00865-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12975-020-00865-2